Osteogenesis Imperfecta Clinical Trial
Official title:
Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI) Is Nintendo Wii an Effective Intervention for Children With Osteogenesis Imperfecta
Children with osteogenesis imperfecta are described as extremely sedentary and therefore
fatigable, which strongly impacts their daily activities. The physical rehabilitation of
these children is a fundamental aspect of treatment.
It has been shown that playing Wii console causes the same increase in energy expenditure
than practicing moderate exercise, while ensuring user safety. This type of physical
exercise with this type of fun game console might have a role in the treatment of OI
children on the physical side but also on the psychological side.
Status | Terminated |
Enrollment | 20 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - - Children affiliated to a social security scheme - Children diagnosed OI by a competent physician of one of the French specialist centers; - OI children type 1 or type 4; - Stable OI (far from a fractional episode of at least two months); - Children without regular activity on the Nintendo Wii console or other interactive console; - Boy or Girl> 6 to 18 years - Parents or person having parental authority affiliated to a social security scheme - Parents or person having parental authority who signed the consent form for the study. Exclusion Criteria: - - Children who can not walk; - Children with severe OI other than type 1 or type 4; - Fracture during the last two months; - Surgical intervention within the last 8 months; - Inability to understand and follow the protocol; - Participation in another clinical study; - Children, parents or holder of parental authority refusing the written consent. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
France | CHU Saint-Etienne | Saint-Etienne |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Saint Etienne | Fondation de France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in physical capacity | Compare the change in physical capacity between training group of children with OI and control group of children with OI. The physical capacity is measured by maximal oxygen consumption VO2 max (ml/min/kg) measured during incremental exercise on cycle ergometer | from baseline to 3 months | No |
Secondary | Change in physical capacity | Compare the change in physical capacity between training group of children with OI and control group of children with OI. The physical capacity is measured by maximal oxygen consumption VO2 max (ml/min/kg) measured during incremental exercise on cycle ergometer | From baseline to 9 months | No |
Secondary | Compare physical inactivity between training group and control group | Physical inactivity will be assessed by the Physical Activity Questionnaire (Q-APS) | Month 3 | No |
Secondary | Compare physical inactivity between training group and control group | Physical inactivity will be assessed by the Physical Activity Questionnaire (Q-APS) | Month 9 | No |
Secondary | Compare functional benefit between training group and control group | The functional benefit will be evaluated by the Functional Independence Measure (FIM) | Month 3 | No |
Secondary | Compare functional benefit between training group and control group | The functional benefit will be evaluated by the Functional Independence Measure (FIM) | Month 9 | No |
Secondary | Compare body fat between training group and control group | Body fat composition will be determined by skinfold measurements | Month 3 | No |
Secondary | Compare body fat between training group and control group | Body fat composition will be determined by skinfold measurements | Month 9 | No |
Secondary | Compare quality of life between training group and control group | The quality of life will be determined the Index Questionnaire Reintegration to Normal Life (IRVN) | Month 3 | No |
Secondary | Compare quality of life between training group and control group | The quality of life will be determined the Index Questionnaire Reintegration to Normal Life (IRVN) | Month 9 | No |
Secondary | Compare muscle strength between training group and control group | The muscle strength is a composite outcome. It will be assessed by: The grip strength (force applied by the hand) The maximal quadriceps muscle strength will be measured using an isokinetic dynamometer "Contrex" |
Month 3 | No |
Secondary | Compare muscle strength between training group and control group | The muscle strength is a composite outcome. It will be assessed by: The grip strength (force applied by the hand) The maximal quadriceps muscle strength will be measured using an isokinetic dynamometer "Contrex" |
Month 9 | No |
Secondary | Compare endurance of lower limbs between training group and control group | The endurance of the lower limbs will be measured by EMG analysis on incremental torque repetitive exercise | Month 3 | No |
Secondary | Compare endurance of lower limbs between training group and control group | The endurance of the lower limbs will be measured by EMG analysis on incremental torque repetitive exercise | Month 9 | No |
Secondary | Compare Energy expenditure of lower limbs between training group and control group | Energy expenditure is a composite outcome. It will be measured by collecting the respiratory exchange and heart rate during endurance, tennis and boxing games using the Nintendo WII | Month 3 | No |
Secondary | Compare Energy expenditure of lower limbs between training group and control group | Energy expenditure is a composite outcome. It will be measured by collecting the respiratory exchange and heart rate during endurance, tennis and boxing games using the Nintendo WII | Month 9 | No |
Secondary | Training tolerance | Reentrainment tolerance is a composite outcome. It will be assessed by : collecting any events related to WII training or any events related to everyday life (fractures, pain,etc.) dropout rate study report |
Baseline from 9 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Recruiting |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 |